Company intelligence / Profile preview

DepYmed, Inc.

Farmingdale, New York, United Statesdepymed.com ↗

Ownership: Private
Development stage: Phase 1

Overview

DepYmed has received FDA clearance to initiate a Phase 1 clinical trial for its lead candidate DPM‑1003 in Rett Syndrome. The company is developing orally bioavailable small molecule PTP1B inhibitors with potential applications in rare diseases, oncology, metabolic disorders, and neurodegenerative conditions. Preclinical data support advancement into human studies; clinical results are pending as the first-in-human trial begins in 2024.[2][3][4][5]

Therapeutic areas: OncologyRare DiseasesNeurologyMetabolic Disorders
Modalities: Small molecules[1][4][5]
Industry: Biotech

Drug pipeline

3 assets

trodusquemine

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on DepYmed, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DepYmed, Inc..

Explore the full profile